R2WA
Beximco Pharmaceuticals Limited (R2WA)
Market Closed
3 Jan, 20:00
XSTU 
€
0. 45
0
0%
€
- Market Cap
- P/E Ratio
12.7% Div Yield
0 Volume
- Eps
€ 0.45
Previous Close Day Range
0.45 0.45
Year Range
0.23 0.49
Earnings results expected in 13 days
Summary
R2WA closed Friday higher at €0.45, an increase of 0% from Thursday's close, completing a monthly increase of 0% or €0. Over the past 12 months, R2WA stock gained 0%.
R2WA is not paying dividends to its shareholders.
The last earnings report, released on Nov 04, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Jan 28, 2025.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on XSTU (EUR).
Want to track R2WA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
R2WA Chart
FAQ
What Is the Beximco Pharmaceuticals Limited(R2WA) Stock Price Today?
The R2WA stock price today is €0.45.
What Stock Exchange Does Beximco Pharmaceuticals Limited Trade On?
Beximco Pharmaceuticals Limited is listed and trades on the XFRA.
What Is the Stock Symbol for Beximco Pharmaceuticals Limited?
The stock symbol for Beximco Pharmaceuticals Limited is "R2WA".
Does Beximco Pharmaceuticals Limited Pay Dividends? What's The Current Dividend Yield?
R2WA is not paying dividends to its shareholders.
What Is the Beximco Pharmaceuticals Limited Market Cap?
As of today, Beximco Pharmaceuticals Limited does not have a market cap available.
What is Beximco Pharmaceuticals Limited Earnings Per Share?
The Beximco Pharmaceuticals Limited EPS is 0.
What Is the Next Beximco Pharmaceuticals Limited Earnings Date?
Beximco Pharmaceuticals Limited will release its next earnings report on Jan 28, 2025.
Did Beximco Pharmaceuticals Limited had any splits?
No, Beximco Pharmaceuticals Limited has never had a stock split.
Beximco Pharmaceuticals Limited Profile
| Drug Manufacturers—Specialty & Generic Industry | Healthcare Sector | - CEO | XSTU Exchange | US0885792061 ISIN |
| Bangladesh Country | 5,500 Employees | 22 Nov 2024 Last Dividend | - Last Split | - IPO Date |
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.
Contact Information
Address: 19 Dhanmondi R/A
Phone: 880 2 5861 1001
Website: https://www.beximcopharma.com
2025 © Marketlog. All Rights Reserved.
